Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers

Molecular Cancer Therapeutics

Volumn 12, Issue 6, 2013, Pages 968-978

  Govindan, Serengulam V ^a   Cardillo, Thomas M ^a   Sharkey, Robert M ^a   Tat, Fatma ^a   Gold, David V ^b   Goldenberg, David M ^a,b  

^a IMMUNOMEDICS INC   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD74 ANTIGEN; DOXORUBICIN; FIRTECAN; MILATUZUMAB; VELTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG TRANSPORT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; CAMPTOTHECIN; CELL ADHESION MOLECULES; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879304805     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1170     Document Type: Article

References (50)

1. Morton PA, Zacheis ML, Giacoletto KS, Manning JA, Schwartz BD. Delivery of nascent MHC class II-invariant chain complexes to lyso-somal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J Immunol 1995;154:137-50.
2. Roche PA, Cresswell P. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 1990;345: 615-8.
3. Roche PA, Teletski CL, Stang E, Bakke O, Long EO. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci U S A 1993;90:8581-5.
4. Binsky I, Haran M, Starlets D, Gore Y, Lantner F, Harpaz N, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A 2007;104:13408-13.
5. Naujokas MF, Morin M, Anderson MS, Peterson M, Miller J. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993;74:257-68.
6. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003; 197:1467-76.
7. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10:6606-11.
8. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104:3705-11.
9. Wraight CJ, van Endert P, Moller P, Lipp J, Ling NR, MacLennan IC, et al. Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem 1990;265:5787-92.
10. Hansen HJ, Ong GL, Diril H, Valdez A, Roche PA, Griffiths GL, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320(Pt 1):293-300.
11. Qu Z, Ma H, Consoino K, Li X, Goldenberg DM. Internalization and cytotoxic effects of a humanized anti-CD74 antibody, LL1. Proc Am Assoc Cancer Res 2002;43:255.
12. Frölich D, Blabetafeld D, Reiter K, Giesecke C, Daridon C, Mei HE, et al. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. Arthritis Res Ther 2012;14:R54.
13. Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9:6567-71.
14. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005; 11:5257-64.
15. Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons. Clin Cancer Res 2005;11:777-86.
16. Chang CH, Sapra P, Vanama SS, Hansen HJ, Horak ID, Goldenberg DM. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106:4308-14.
17. Kaufman J, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, et al. First trial of humanized anti-CD74 monoclonal antibody (MAb), milatuzumab, in multiple myeloma. ASH Annual Meeting Abstracts 2008;112:3697.
18. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Iwashige H, Aridome K, et al. Invariant chain expression in gastric cancer. Cancer Lett 2001; 168:87-91.
19. Gold DV, Stein R, Burton J, Goldenberg DM. Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol 2010;4:1-12.
20. Zheng YX, Yang M, Rong TT, Yuan XL, Ma YH, Wang ZH, et al. CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer. World J Gastroenterol 2012;18:2253-61.
21. Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, et al. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol 2010;100:177-86.
22. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, Berroa Garcia LY, Ried T, Loo M, et al. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer 2012;131:49-58.
23. Ioachim HL, Pambuccian SE, Hekimgil M, Giancotti FR, Dorsett BH. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol 1996;20:64-71.
24. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639-51.
25. Choi JW, Kim Y, Lee JH, Kim YS. CD74 expression isincreasedin highgrade, invasive urothelial carcinoma of the bladder. Int J Urol 2013;20:251-5.
26. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61.
27. Moon SJ, Govindan SV, Cardillo TM, D'Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 2008; 51:6916-26.
28. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
29. Rivory LP. Metabolism of CPT-11. Impact on activity. Ann N Y Acad Sci 2000;922:205-15.
30. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011;17:3157-69.
31. Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. Epratuzu-mab-SN-38: a new antibody-drug conjugate for the therapy of hema-tologic malignancies. Mol Cancer Ther 2012;11:224-34.
32. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556s-63s.
33. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 2006;6: 1341-53.
34. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010;51:747-55.
35. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-78.
36. Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s-45s.
37. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-85.
38. Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 2007;7:2.
39. Stein R, Basu A, Chen S, Shih LB, Goldenberg DM. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancar-cinoma monoclonal antibody. Int J Cancer 1993;55:938-46.
40. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845-9.
41. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012;12:873-90.
42. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastu-zumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011;17:6437-47.
43. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85.
44. Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opin Biol Ther 2012;12:1415-21.
45. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20:1131-49.
46. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97.
47. Sharkey RM, Karacay H, Govindan SV, Goldenberg DM. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther 2011;10:1072-81.
48. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Del Rev 2008;60:1421-34.
49. Giovanella BC, Harris N, Mendoza J, Cao Z, Liehr J, Stehlin JS. Dependence of anticancer activity of camptothecins on maintaining their lactone function. Ann N Y Acad Sci 2000;922:27-35.
50. Zhao H, Lee C, Sai P, Choe YH, Boro M, Pendri A, et al. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J Org Chem 2000;65:4601-6.